Revelation Biosciences Inc. announced that the independent Safety Monitoring Committee (SMC) reviewed data for 14 of patients treated in the Phase 1b clinical study of REVTx-99b for the treatment of allergic rhinitis and patients with chronic nasal congestion without polyps. Based on those findings, the SMC recommended the continuation of the study without modification. The clinical study is being conducted in Australia.

The Phase 1b, randomized, double-blind, placebo-controlled, crossover design study is expected to complete enrollment in the third quarter of 2022. The primary endpoint is to evaluate the effects of REVTx-99b versus placebo on safety and tolerability. Key secondary endpoints include allergy symptoms (Total Nasal Symptom Score) and peak nasal inspiratory flow elicited by nasal allergen challenge.

The study will have two cohorts: one cohort will receive study drug before the nasal allergen challenge (the prophylactic cohort) and the second cohort will receive study drug after the nasal allergen challenge (the treatment cohort).